Fig. 3From: Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspectiveProbability of achieving highest NMB: Cost-effectiveness Acceptability Curve with a secukinumab 150 mg, b secukinumab 300 mg, c secukinumab 300 mg. ADA, adalimumab; APR, apremilast; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; SEC, secukinumab; UST, ustekinumabBack to article page